Largactil

Chlorpromazine, the active ingredient in Largactil, is a phenothiazine antipsychotic presented as an oral dosage form for systemic use. It is employed in the management of schizophrenia, acute psychotic states and manic episodes, primarily in adult patients. GNH USA supplies Largactil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Chlorpromazine acts on central nervous system pathways involved in psychosis and mood regulation. - Schizophrenia: helps reduce hallucinations, delusions and thought disorder. - Acute psychosis: stabilises severe agitation and psychotic symptoms. - Manic episodes: moderates elevated mood, hyperactivity and irritability.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dry mouth: reduced salivation causing discomfort. - Constipation: slowed gastrointestinal motility. - Orthostatic hypotension: dizziness upon standing. - Weight gain: increased appetite leading to weight increase. - Extrapyramidal symptoms: mild tremor or rigidity.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements. - Severe hypotension: marked drop in blood pressure. - Agranulocytosis: dangerous reduction in white blood cells. - Seizures: occurrence of convulsive episodes. - Hepatotoxicity: liver enzyme elevations or injury.

Before initiating therapy, consider the following safety measures. - Cardiac monitoring: assess baseline ECG in patients with cardiac risk. - Diabetes screening: monitor blood glucose in susceptible individuals. - Liver function: evaluate hepatic enzymes for patients with liver disease. - Elderly patients: start at low dose and watch for confusion or falls. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Chlorpromazine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, opioids): risk of profound sedation and respiratory depression. - Anticholinergic agents: additive anticholinergic burden leading to severe constipation or urinary retention. - QT‑prolonging drugs (e.g., quinidine, haloperidol): heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase chlorpromazine plasma levels. - Antihypertensives: additive hypotensive effect, monitor blood pressure. - Alcohol: enhances sedative properties, advise limited intake.